MNPR - Monopar Already Traded Its Outstanding Share Count and about to Turn Its Float again

2024-02-23 10:22:53 ET

DENVER, Colo., Feb 23, 2024 (www.247marketnews.com)- Monopar Therapeutics Inc. (NASDAQ: MNPR ) has already exceeded its outstanding share count and is about to turn its float over for the third time this morning.

Monopar is trading at $1.3366, up $0.2166 (+19.34%), on over 15 million shares.

Its 52-week range is $0.2739 to $3.4102.

Monopar’s reported outstanding share count is 14.87M and its float is 5.75M.

Yesterday, Monopar announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 first-in-class radiopharma program, which targets cancers expressing the urokinase plasminogen activator receptor (uPAR), including a majority of all triple-negative breast, colorectal, and pancreatic cancers.

Monopar recently announced it received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients. “As we prepare to launch this clinical trial, we are encouraged by the significant, precise, and durable accumulation we are seeing in tumors and the corresponding therapeutic benefit in preclinical human tumor xenograft models,” said Andrew Cittadine, Monopar’s Chief Operating Officer. “We are aiming to present these promising preclinical results at an upcoming scientific meeting.”

The post Monopar Already Traded Its Outstanding Share Count and about to Turn Its Float again first appeared on 24/7 MarketNews .

For further details see: